European Statistical Meeting
Generating evidence for
Health Technology Assessment
Thursday 25th September 2014, Berlin
The importance of HTA has increased substantially over the last few
years. In order to obtain reimbursement, it has become critical for
manufacturers to provide additional evidence about their products in a
real-world setting to satisfy the requirements of the various national
HTA bodies.
This meeting will provide a forum to hear about the latest developments
in the applications of HTA methods from representatives from European
regulatory bodies, and from practitioners in the pharmaceutical industry
and academia.
Presenters include:
Ralf Bender, IQWIG
Biometrical issues in the framework of benefit assessment
Chrissie Fletcher, Amgen
Subgroup analyses for regulatory and HTA submissions
Omar Dabbous, GSK
Analytical Strategy, Credibility and Rigor of Evidence for HTA
Tim Auton, Astellas
Designing better observational studies: The role of the pharmaceutical statistician
Christoph Gerlinger, Bayer
Deriving minimally important difference for PRO data
Marie-Ange Paget, Lilly
Meeting local HTA requirements – challenges for the HTA statistician
Fred Sörenson, Xcenda
Applying Real-World Data in HTA – Why one size does not fit all
Venue
Bayer HealthCare Pharmaceuticals
Müllerstrasse 178
13352 Berlin
Germany
Registration Costs
Fee includes lunch & refreshments
Registrationon/before 15 August
Industry €160
Academic €100
Registration after 15 August
Industry €190
Academic €120
TO REGISTER PLEASE GO TO:
www.efspi.org
OR
Contact:
EFSPI Secretariat
Tel: +44 (0)1625 664549
[log in to unmask]
You may leave the list at any time by sending the command
SIGNOFF allstat
to [log in to unmask], leaving the subject line blank.
|